Skip to content
Sachs Forum 2025 Slide Presentation
View Presentation
Strategic Partnering
News
Presentations
Contact Us
Strategic Partnering
News
Presentations
Contact Us
Invest now
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Strategic Partnering
News
Presentations
Contact Us
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Strategic Partnering
News
Presentations
Contact Us
BirchBioMed is Cleared to Begin First-of-its-kind Phase II Clinical Trial for Ground-Breaking Anti-Scarring Drug
02-016-18-Birch-Phase-II-Release_FINAL1
